Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.

Abstract: Artificial tissue constructs (TCs), methods of making the TCs, uses thereof, and kits comprising the TCs are provided. TCs are useful for vaccine evaluation for human adult, human non-newborn, and newborns.

Abstract: A compound has formula (I), where R is selected from a methyl group or an ethyl group: The compound can be hydroxy acid forms thereof, the pharmaceutically acceptable salts of the hydroxy acids and pharmaceutically acceptable prodrugs and solvates of the compounds and of the hydroxy acid forms thereof. The compounds can be used in the prevention or treatment of: neurodegenerative or neurological diseases, cognitive impairment, diseases with impaired APP metabolism, inflammation or inflammatory processes, or epilepsy, epileptic seizures and convulsions.

Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.

Abstract: Compressive plates of the placental insertion site for use in cases of placenta previa includes: an axle plate including a primary plate which is fixed, a threaded bar that has machined two plates and a diameter reduction section, a secondary plate having a hole with a diameter and a shape that allows the introduction of the bar, a punch with conical tip, a nut and a locknut, and a protective cover. The punch pierces the front and back walls of the uterus corresponding to the placental insertion site. Then, the secondary plate is introduced that approaches to the primary plate until obtaining enough pressure to stop the bleeding, the nut and locknut are placed, and, finally, the protective cover is screwed.

Abstract: The invention relates to a compressive system for reducing edge bleeding in classical hysterotomy in cases of placenta praevia, said system comprising: a compressive device formed by two compressive bars and bracketing members; and a clamp for applying the compressive device, said clamp comprising two handles, two jaws, a rotation nut, two protuberances and a threaded adjustment nut. The clamp allows the opening of the compressive bars. The device is applied to the edges of the hysterotomy and, subsequently, the clamp is withdrawn.

Abstract: The present invention relates to a hermetic occlusion surgical clamp for the female cervix to be used in case of placenta previa, including compression jaws with a spring (5.1) and semi-conical sections (5.2) and at the end of each jaw a machined semi-cylinder (5.3), and a pull-down cylinder with a machining that generated two arms (6.2) with a hole that is joined by a pin (5.4) that connects the jaws to the pull-down cylinder. The pull-down cylinder also includes a thread (6.4), which allows you to screw on a screw (6.5) to open or close the jaws. Finally, the surgical clamp also includes a shell which is a hollow cylinder along its longitudinal axis, which covers semi-conical sections (5.2) of the jaws to leave a thread length (6.4) free that allows placement of the screw (6.5).

Abstract: Artificial tissue constructs (TCs), methods of making the TCs, uses thereof, and kits comprising the TCs are provided. TCs are useful for vaccine evaluation for human adult, human non-newborn, and newborns.

Abstract: The invention relates to a compressive system for reducing edge bleeding in classical hysterotomy in cases of placenta praevia, said system comprising: a compressive device formed by two compressive bars and bracketing members; and a clamp for applying the compressive device, said clamp comprising two handles, two jaws, a rotation nut, two protuberances and a threaded adjustment nut. The clamp allows the opening of the compressive bars. The device is applied to the edges of the hysterotomy and, subsequently, the clamp is withdrawn.

Abstract: Compressive plates of the placental insertion site for use in cases of placenta previa includes: an axle plate including a primary plate which is fixed, a threaded bar that has machined two plates and a diameter reduction section, a secondary plate having a hole with a diameter and a shape that allows the introduction of the bar, a punch with conical tip, a nut and a locknut, and a protective cover. The punch pierces the front and back walls of the uterus corresponding to the placental insertion site. Then, the secondary plate is introduced that approaches to the primary plate until obtaining enough pressure to stop the bleeding, the nut and locknut are placed, and, finally, the protective cover is screwed.

Abstract: The present invention relates to a hermetic occlusion surgical clamp for the female cervix to be used in case of placenta previa, including compression jaws with a spring (5.1) and semi-conical sections (5.2) and at the end of each jaw a machined semi-cylinder (5.3), and a pull-down cylinder with a machining that generated two arms (6.2) with a hole that is joined by a pin (5.4) that connects the jaws to the pull-down cylinder. The pull-down cylinder also includes a thread (6.4). which allows you to screw on a screw (6.5) to open or close the jaws. Finally, the surgical clamp also includes a shell which is a hollow cylinder along its longitudinal axis, which covers semi-conical sections (5.2) of the jaws to leave a thread length (6.4) free that allows placement of the screw (6.5).

Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.

Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.

Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.

Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.

Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the tissues of the immune system in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates and other materials in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system, coupled with disease models to provide a more complete representation of an immune response.

Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system.

Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.

Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.